Table 8.
HIV-1 DNA vs anti-Tat humoral immune responses, adjusted for treatment groups and antiretroviral drug regimens
| HIV-1 DNA (log 10 copies/10 6 CD4 + ) | Year (a) | Estimate (b) | 95% CI (c) | p value |
|---|---|---|---|---|
| Anti-Tat humoral response | ||||
| IgM+ and IgG+ | 2nd | −0.17 | −0.28; −0.05 | 0.0036 |
| 3rd | −0.26 | −0.41; −0.10 | 0.0012 | |
| IgM+, IgG+ or IgA+ | 2nd | 0.02 | −0.08; 0.12 | 0.3837 |
| 3rd | −0.17 | −0.32; −0.01 | 0.0356 | |
| Ab Negative | 2nd | −0.13 | −0.30; 0.04 | 0.1345 |
| 3rd | −0.23 | −0.46; −0.00 | 0.0546 | |
| Treatment groups | ||||
| Tat 7.5 μg, 3x | 2nd | −0.01 | −0.14; 0.12 | 0.8997 |
| 3rd | 0.03 | −0.18; 0.25 | 0.7572 | |
| Tat 7.5 μg, 5x | 2nd | −0.10 | −0.17; 0.03 | 0.1794 |
| 3rd | −0.25 | −0.43; −0.10 | 0.0057 | |
| Tat 30 μg, 3x | 2nd | −0.16 | −0.35; 0.03 | 0.0975 |
| 3rd | −0.53 | −0.73; −0.33 | <0.0001 | |
| Tat 30 μg, 5x | 2nd | −0.13 | −0.29; 0.02 | 0.0887 |
| 3rd | −0.12 | −0.31; 0.07 | 0.2156 | |
| Tat 30 μg, 3x vs Tat 7.5 μg, 3x | 3rd | −0.56 | −1.02; −0.10 | 0.0050 |
| Antiretroviral regimens | ||||
| NNRTI-based or NRTI | −0.05 | −0.16; 0.05 | 0.2971 | |
| PI-based | −0.25 | −0.36; −0.15 | <0.0001 | |
| NNRTI-based or NRTI vs PI-based | 0.20 | 0.06; 0.34 | 0.0047 |
(a)Year since first immunization: 48, 72, 84, 96 weeks (2nd year); 108, 120, 132, 144 weeks (3rd year); (b)Least square means; (c)confidence interval.
Multivariate analysis of variance for repeated measures of longitudinal samples from 136 individuals.